Rigel’s current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP
. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA)
and IgA nephropathy (IgAN)
. In addition, Rigel has product candidates in development with partners BerGenBio AS
, Daiichi Sankyo
, and Aclaris Therapeutics
Recent NewsMore »
|08/01/17||Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update|
|Conference Call and Webcast Today at 5:00PM Eastern Time
SOUTH SAN FRANCISCO, Calif., Aug. 1, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the second quarter and six months ended June 30, 2017.
On June 19, 2017, Rigel announced the U.S Food & Drug Administration (FDA) had accepted for filing its New Drug Application (NDA) for the use of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persis... |
|07/25/17||Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results|
|SOUTH SAN FRANCISCO, Calif., July 25, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its second quarter financial results after market close on Tuesday, August 1, 2017. Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results and provide a company update.
Participants can access the live conference call by dialing 855-892-1489 (... |
|06/22/17||Rigel Announces Oral Presentation of TAVALISSE™ (fostamatinib disodium) Phase 3 Clinical Data at the European Hematology Association 22nd Annual Congress|
|SOUTH SAN FRANCISCO, Calif., June 22, 2017 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that data from its FIT Phase 3 clinical program evaluating the safety and efficacy of TAVALISSE™ (fostamatinib disodium) in patients with chronic or persistent immune thrombocytopenia (ITP) will be presented on Saturday, June 24, 2017, from 12:30 - 12:45pm (CEST) at the European Hematology Association 22nd Annual Congress (EHA) in Madrid, Spain. Earlier this week, Rigel announced ... |
Upcoming EventsMore »
There are currently no events scheduled.
|Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.|